Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083 (2023)
Attributed to:
MRC Centre for Global Infectious Disease Analysis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.lana.2022.100416
Publication URI: http://dx.doi.org/10.1016/j.lana.2022.100416
Type: Journal Article/Review
Parent Publication: The Lancet Regional Health - Americas